$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
How to tell the authenticity of tepotinib?
2025-10-19 11:44:20
Check Details
How much does a box of pemetinib 2023 cost?
2025-10-19 11:44:20
Check Details
How effective is the "legendary broad-spectrum" anti-cancer drug larotrectinib? The objective response rate is as high as 75%!
2025-10-19 11:44:20
Check Details
Focusing on anti-tumor small molecule drugs, Yuanyuankang’s EGFR/HER2 inhibitor TY-4028 has been approved for clinical use in the United States
2025-10-19 11:44:20
Check Details
CSPC Pharmaceutical Group: Antibody-drug conjugate CPO301 obtained FDA clinical trial approval
2025-10-19 11:44:20
Check Details
What is the effect of nivolumab on lung cancer
2025-10-19 11:44:20
Check Details
Focus on NSCLC, AstraZeneca’s ADC new drug submits clinical application in China
2025-10-19 11:44:20
Check Details
Contraindications for taking nivolumab
2025-10-19 11:44:20
Check Details
How often should you lose nivolumab
2025-10-19 11:44:20
Check Details
Conditional activation blocks VISTA to inhibit solid tumors, and the US FDA approves the new drug research application of SNS-101
2025-10-19 11:44:20
Check Details
Acting on the tumor microenvironment, Parthenon announced that the self-developed drug PRTH-101 has completed the first patient administration in the phase I clinical trial
2025-10-19 11:44:20
Check Details
Innovent Biologics/Eli Lilly's RET inhibitor "Seputinib" is officially commercialized in China_Canghule
2025-10-19 11:44:20
Check Details
1
2
...
4113
4114
4115
4116
4117
4118
4119
...
4155
4156
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Durvalumab Safety Profile: Managing Immune-Related Adverse Events (irAEs) in Clinical Practice
2
Zolbetuximab Combination Therapy: Global Efficacy and Safety Profile in CLDN18.2-Positive Advanced Gastric Cancer
3
Managing Mitotane Resistance in Adrenocortical Carcinoma: Strategies and Global Options
4
Trametinib & Dabrafenib in 2026: A Global Guide to Treating BRAF-Mutant Cancers
5
A Guide to Safely Stopping Mitotane: Why Tapering is Essential and How to Manage
6
Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma
7
Erlotinib: Targeting EGFR Mutations to Precisely Inhibit Non-Small Cell Lung Cancer Growth
8
Tofacitinib: The Role and Considerations of an Oral JAK Inhibitor in Autoimmune Disease Treatment
9
Tucatinib: Redefining the Treatment Landscape for HER2-Positive Cancers with High Selectivity
10
Complete Guide to Garsorasib Resistance Mechanisms and Follow-Up Treatments
11
Vemurafenib: An Oral Targeted Therapy for BRAF V600E-Mutant Melanoma
12
Vemurafenib: Precision Targeting of BRAF Mutation, Revolutionizing Melanoma Treatment